Men on gonadotropin-releasing hormone agonists (Lupron, etc) for prostate cancer
August 2001
Men on gonadotropin-releasing hormone agonists (Lupron, etc) for prostate cancer seem to have a higher risk of osteoporosis.
This makes sense.
These drugs slow the growth of prostate cancer by suppressing testosterone production.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote